US 12,453,771 B2
Methods of treating cancer using anti-CD137 antibodies
Christopher Carl Frye, Bargersville, IN (US); Michael Dewain Kalos, Brooklyn, NY (US); Helen Kotanides, Norwalk, CT (US); and Stephanie Lynn Sandefur, Indianapolis, IN (US)
Assigned to ELI LILLY AND COMPANY, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Nov. 1, 2022, as Appl. No. 18/051,761.
Application 18/051,761 is a division of application No. 16/750,842, filed on Jan. 23, 2020, granted, now 11,512,134.
Application 16/750,842 is a continuation of application No. 16/497,493, granted, now 10,906,983, issued on Feb. 2, 2021, previously published as PCT/US2018/043632, filed on Jul. 25, 2018.
Claims priority of provisional application 62/539,687, filed on Aug. 1, 2017.
Prior Publication US 2023/0279134 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/3955 (2013.01) [C07K 16/2878 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01)] 13 Claims
 
1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-human CD137 antibody comprising a heavy chain variable region and a light chain variable region; wherein the heavy chain variable region comprises a HCDR1 having the amino acid sequence of SEQ ID NO: 2, a HCDR2 having the amino acid sequence of SEQ ID NO: 3, and a HCDR3 having the amino acid sequence of SEQ ID NO: 4; wherein the light chain variable region comprises a LCDR1 having the amino acid sequence of SEQ ID NO: 5, a LCDR2 having the amino acid sequence of SEQ ID NO: 6, and a LCDR3 having the amino acid sequence of SEQ ID NO: 7.